Xiaozhen Jiao

Prof. Xiaozhen Jiao


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Molecules
Verified
Journal Article
Open access
PDF file
YYYangyang Yao
Yangyang Yao
RLRenze Li
Renze Li
XLXiaoyu Liu
Xiaoyu Liu
FYFeilong Yang
Feilong Yang
YYYing Yang
Ying Yang
PXPing Xie
Ping Xie
Inhibitors of Rho kinase (ROCK) have potential therapeutic applicability in a wide range of diseases, such as hypertension, stroke, asthma and glaucoma. In a previous article, we described the lead discovery of DL0805, a new ROCK I inhibitor, showing potent inhibitory activity (IC50 6.7 μM). Herein, we present the lead optimization of compound DL0805, resulting in the discovery of 24- and 39-fold more-active analogues 4a (IC50 0.27 μM) and 4b (IC50 0.17 μM), among other active analogues. Moreover, ex-vivo studies demonstrated that 4a and 4b exhibited comparable vasorelaxant activity to the approved drug fasudil in rat aortic rings. The research of a preliminary structure–activity relationship (SAR) indicated that the target compounds containing a β-proline moiety have improved activity against ROCK I relative to analogues bearing an α-proline moiety, and among the series of the derivatives with a β-proline-derived indazole scaffold, the inhibitory activity of the target compounds with a benzyl substituent is superior to those with a benzoyl substituent.

1 June 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
XLXiaoyu Liu
Xiaoyu Liu
PCPanpan Chen
Panpan Chen
XLXiaoyu Li
Xiaoyu Li
MBMingyu Ba
Mingyu Ba
XJXiaozhen Jiao
Xiaozhen Jiao
PXPing Xie
Ping Xie

18 May 2012 in Molecules
Verified
Journal Article
Open access
PDF file
LGLi-Li Gong
Li-Li Gong
JPJianhao Peng
Jianhao Peng
LFLianhua Fang
Lianhua Fang
PXPing Xie
Ping Xie
KSKun Si
Kun Si
GDGuanhua Du
Guanhua Du
Rho-kinase has been suggested as a potential therapeutic target in the treatment of cardiovascular diseases. The Rho-kinase signaling pathway is substantially involved in vascular contraction. The aim of the present study was to evaluate the vasorelaxant effects of Rho kinase inhibitor DL0805 in isolated rat aortic rings and to investigate its possible mechanism(s). It was found that DL0805 exerted vasorelaxation in a dose-dependent manner in NE or KCl-induced sustained contraction and partial loss of the vasorelaxation under endothelium-denuded rings. The DL0805-induced vasorelaxation was significantly reduced by the nitric oxide synthase inhibitor Nω-nitro-L-arginine methyl ester, the guanylate cyclase inhibitor methylene blue and the cyclooxygenase inhibitor indomethacin. The voltage-dependent K+ channel blocker 4-aminopyridine remarkably attenuated DL0805-induced relaxations. However, the ATP-sensitive K+ channel blocker glibenclamide and Ca2+-activated K+ channel blocker tetraethylammonium did not affect the DL0805-induced relaxation. In the endothelium-denuded rings, DL0805 also reduced NE-induced transient contraction and inhibited contraction induced by increasing external calcium. These findings suggested that DL0805 is a novel vasorelaxant compound associated with inhibition of Rho/ROCK signaling pathway. The NO-cGMP pathway may be involved in the relaxation of DL0805 in endothelium-intact aorta. The vasorelaxant effect of DL0805 is partially mediated by the opening of the voltage-dependent K+ channels.

9 February 2018 in Synthetic Communications
Verified
Journal Article
Closed access
XLXiaoyu Liu
Xiaoyu Liu
HYHongguang Yang
Hongguang Yang
XSXiang Shi
Xiang Shi
FYFeilong Yang
Feilong Yang
XJXiaozhen Jiao
Xiaozhen Jiao
PXPing Xie
Ping Xie
Eliglustat, a ceramide glucosyltransferase inhibitor, was synthesized in six steps with 28.4% overall yield. The key features include the use of a diastereoselective aldol reaction to construct two contiguous stereocenters and a selective sulfonylation of a 1,3-diol catalyzed by dibutyltin oxide. GRAPHICAL ABSTRACT

27 April 2021 in Organic Letters
Verified
Journal Article
Closed access
YWYong Wang
Yong Wang
ZWZhenwei Wang
Zhenwei Wang
ZWZhe Wang
Zhe Wang
XLXiaoyu Liu
Xiaoyu Liu
YJYingjun Jiang
Yingjun Jiang
PXPing Xie
Ping Xie

5 April 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
HYHongguang Yang
Hongguang Yang
XLXiaoyu Liu
Xiaoyu Liu
XSXiang Shi
Xiang Shi
FYFeilong Yang
Feilong Yang
XJXiaozhen Jiao
Xiaozhen Jiao
PXPing Xie
Ping Xie
An efficient stereoselective synthetic approach to colomitides, 2,7-dioxabicyclo[3.2.1]octane-type natural products, is reported. Key steps are a stereocontrolled aldol reaction and a gold-catalyzed cycloisomerization. This synthetic strategy has been applied for the first asymmetric total synthesis of the proposed colomitides and their possible diastereomers. Comparison of their 1H and 13C NMR spectra and specific rotations with those of the natural product revealed that the structure of colomitide A should be revised to 1c, and that the absolute stereochemistries of colomitides A and B are 2′R,4R,5R,8S,1R and 2′R,4S,5R,8S,1R.